LONDON (ShareCast) - (Sharecast News) - Shares in N4 Pharma rocketed on Wednesday, after it announced that 'Nuvec' loaded with coronavirus plasmid had successfully transfected human embryonic kidney (HEK) cells in vitro, and induced an expression of the spike protein in the cells.
The AIM-traded pharmaceutical firm said the result was the second stage of its three-stage plan for its Covid-19 proof-of-concept project, being undertaken with Evotec International.

It meant that the project would now move into its third stage, being the pre-in vivo study, to demonstrate expression of the spike protein in target cells in a murine, or rodent, target.

"We are delighted to have achieved in vitro transfection of HEK cells with Nuvec loaded with coronavirus plasmid," said chief executive officer Nigel Theobald.

"We now move straight to the third stage of our Covid-19 project with our pre-invivo study at Evotec.

"The global pandemic continues to dominate all of our lives and we are extremely excited to be moving onto the next stage of our Covid-19 project, the successful outcome of which will determine our next work streams in this area and how we might collaborate with appropriate partners interested in any advantage our Nuvec delivery system may provide."

At 1435 BST, shares in N4 Pharma were 57.23% higher at 12.5p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE